|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Immunosuppression for in vivo research: state-of-the-at protocols and experimental approaches显示文摘几乎,用非自体同源的房间,织物或机关移植的每试验性的治疗策略在临床的翻译前在小、大的动物模型被测试。因为这些策略在大多数情况中要求免疫力的抑制,抑制免疫力的协议是在移植实验的一个关键元素。然而,没有详细知识,标准抑制免疫力的协议经常在特别试验性的背景以内并且在选择模型种类关于他们的功效被使用。如此的协议的优化对到人的病人的试验性的结果的翻译恰当,因此,保证推进调查。这评论与种类特定的药 metabolization 和副作用的考虑关于抑制免疫力的药类以及他们的剂量和应用程序政体总结当前的知识。它也总结新奇 immunomodulatory 策略的当代的知识,例如间充质的干细胞或抗体的使用。因此,这评论被打算用作一个最先进的概要让研究人员精制应用试验性的免疫力的抑制和 immunomodulation 策略提高现出症状之前的潜的移植研究的预兆的价值。 | Rita Diehl Fabienne Ferrara Claudia Müller Antje Y Dreyer Damian D McLeod Stephan Fricke Johannes Boltze | 2017 | Cellular & Molecular Immunology2017，14，2： | 5 |
| 2 | Imaging genetics of FOXP2 in dyslexia显示文摘 | Arndt Wilcke Carolin Ligges Jana Burkhardt Michael Alexander Christiane Wolf Eifi Quente Petr Ahnert Per Hoffmann Albert Bcher Bertram Muller-Myhsok Sven Cichon Johannes Boltze and Holger Kirsten | | 0，，： | 1 |
| 3 | Transplantation of placenta-derived mesenchymal stromal cells upon experimental stroke in rats显示文摘 | Alexander Kranz Daniel-Christoph Wagner Manja Kamprad Markus Scholz Uwe Richard Schmidt Franziska Nitzsche Zami Aberman Frank Emmrich Ute-Maria Riegelsberger Johannes Boltze | 2009 | Brain Research2009，，： | 1 |
| 4 | Exploring novel experimental treatments for major neurodegenerative disorders显示文摘Acute and chronic neurodegenerative disorders such as ischemic stroke or Alzheimer's disease(AD)impose a major burden on patients,their relatives,caregivers,and health care systems in general.The socioeconomic impact of neurodegenerative disorders is anticipated to escalate due to a globally ageing population and the increasing prevalence of sedentary lifestyle and inappropriate dietary habits.On the contrary. | Xunming Ji Piotr Walczak Johannes Boltze | 2023 | Neuroprotection2023，1，2： | 0 |
| 5 | Preserving cognitive function in patients with Alzheimer's disease:The Alzheimer's disease neuroprotection research initiative(ADNRI)显示文摘The global trend toward aging populations has resulted in an increase in the occurrence of Alzheimer's disease(AD)and associated socioeconomic burdens.Abnormal metabolism of amyloid-β(Aβ)has been proposed as a significant pathomechanism in AD,supported by results of recent clinical trials using anti-Aβantibodies.Nonetheless,the cognitive benefits of the current treatments are limited.The etiology of AD is multifactorial,encompassing Aβand tau accumulation,neuroinflammation,demyelination,vascular dysfunction,and comorbidities,which collectively lead to widespread neurodegeneration in the brain and cognitive impairment.Hence,solely removing Aβfrom the brain may be insufficient to combat neurodegeneration and preserve cognition.To attain effective treatment for AD,it is necessary to(1)conduct extensive research on various mechanisms that cause neurodegeneration,including advances in neuroimaging techniques for earlier detection and a more precise characterization of molecular events at scales ranging from cellular to the full system level;(2)identify neuroprotective intervention targets against different neurodegeneration mechanisms;and(3)discover novel and optimal combinations of neuroprotective intervention strategies to maintain cognitive function in AD patients.The Alzheimer's Disease Neuroprotection Research Initiative's objective is to facilitate coordinated,multidisciplinary efforts to develop systemic neuroprotective strategies to combat AD.The aim is to achieve mitigation of the full spectrum of pathological processes underlying AD,with the goal of halting or even reversing cognitive decline. | Jie Liu Heleen van Beusekom Xian-Le Bu Gong Chen Paulo Henrique Rosado de Castro Xiaochun Chen Xiaowei Chen Andrew N.Clarkson Tracy D.Farr Yuhong Fu Jianping Jia Jukka Jolkkonen Woojin Scott Kim Paula Korhonen Shen Li Yajie Liang Guang-Hui Liu Guiyou Liu Yu-Hui Liu Tarja Malm Xiaobo Mao Joaquim Miguel Oliveira Mike M.Modo Pedro Ramos-Cabrer Karsten Ruscher Weihong Song Jun Wang Xuanyue Wang Yun Wang Haitao Wu Lize Xiong Yi Yang Keqiang Ye Jin-Tai Yu Xin-Fu Zhou Marietta Zille Colin L.Masters Piotr Walczak Boltze Johannes Xunming Ji Yan-Jiang Wang | 2023 | Neuroprotection2023，1，2： | 0 |
| 6 | Activation of neurogenesis in the hippocampus is a novel therapeutic target for Alzheimer's disease显示文摘The pathologies associated with age-related brain dysfunction,including Alzheimer's disease(AD),Parkinson's disease,Lewy body dementia,and vascular dementia,often share similarities across multiple diseases.1 While various factors,such as amyloidβ,Tau protein,α-synuclein,chronic inflammation,and impaired cerebral microcirculation have been suggested as potential therapeutic targets,addressing a single factor is unlikely to be sufficient in preventing or treating age-related brain dysfunction.Drawing from these observations. | Akihiko Taguchi Yuka Okinaka Akiko Takeda Takayuki Okamoto Johannes Boltze Carsten Claussen Sheraz Gul | 2023 | Neuroprotection2023，1，2： | 0 |
| 7 | Mononuclear cell therapy of neonatal hypoxic-ischemic encephalopathy in preclinical versus clinical studies:A systematic analysis of therapeutic efficacy and study design显示文摘Background:Hypoxic-ischemic encephalopathy(HIE)is a devastating condition affecting around 8.5 in 1000 newborns globally.Therapeutic hypothermia(TH)can reduce mortality and,to a limited extent,disability after HIE.Nevertheless,there is a need for new and effective treatment strategies.Cell-based treatments using mononuclear cells(MNCs),which can be sourced from umbilical cord blood,are currently being investigated.Despite promising preclinical results,there is currently no strong indicator for the clinical efficacy of the approach.This analysis aimed to provide potential explanations for this discrepancy.Methods:A systematic review and meta-analysis were conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analysis guidelines.Preclinical and clinical studies were retrieved from PubMed,Web of Science,Scopus,and clinicaltrials.gov using a predefined search strategy.A total of 17 preclinical and 7 clinical studies were included.We analyzed overall MNC efficacy in preclinical trials,the methodological quality of preclinical trials,and relevant design features in preclinical versus clinical trials.Results:There was evidence for MNC therapeutic efficacy in preclinical models of HIE.The methodological quality of preclinical studies was not optimal,and statistical design quality was particularly poor.However,methodological quality was above the standard in other fields.There were significant differences in preclinical versus clinical study design including the use of TH as a baseline treatment(only in clinical studies)and much higher MNC doses being applied in preclinical studies.Conclusions:Based on the analyzed data,it is unlikely that therapeutic effect size is massively overestimated in preclinical studies.It is more plausible that the many design differences between preclinical and clinical trials are responsible for the so far lacking proof of the efficacy of MNC treatments in HIE.Additional preclinical and clinical research is required to optimize the application of MNC for experimental HIE treatment. | Alexander M.Scrutton Francesca Ollis Johannes Boltze | 2023 | Neuroprotection2023，1，2： | 0 |
| 8 | Mitigating the impact of mechanisms causinggneuronal degeneration显示文摘Primary and secondary neurodegeneration is a pathological hallmark of numerous central nervous system(CNS)disorders.Although many mechanisms leading to neurodegeneration are well understood,previous approaches aiming at providing protection from neurodegeneration were often futile.A potential explanation may be that recent research discovered additional pathomechanisms leading to neurodegeneration.Thus,simply targeting single neurodegenerative mechanisms may only have minor therapeutic impact.Addressing multiple neurodegenerative mechanisms may be a more viable strategy.Moreover,the restoration of lost brain tissue turned out to be a very complex endeavor.1 Despite making some initial progress with the use of biocompatible scaffolds and hydrogels. | Xunming Ji Piotr Walczak Johannes Boltze | 2024 | Neuroprotection2024，2，1： | 0 |
| 9 | Join us on an amazing journey towards next-generation treatments for CNS disorders:Launch of Neuroprotection,a new high-quality journal in translational neuroscience显示文摘Translational medicine in neurodegenerative and neurovascular diseases is approaching a breakthrough point.Recent years have led to dramatic progress in both experimental and clinical research.Based on a much better and continuously increasing understanding of disease mechanisms,progression and pathophysiology,new therapies with an improved translational potential to protect tissue either against acute or chronic degeneration and even approaches potentially capable of repairing damaged brain tissue are emerging. | Xunming Ji Piotr Walczak Heleen M.M.van Beusekom Ana I.Casas Andrew Clarkson Tracy Farr Jukka Jolkkonen Yajie Liang Michel M.Modo Paulo H.Rosado-de-Castro Karsten Ruscher Yan-Jiang Wang Haitao Wu Marietta Zille Shen Li Johannes Boltze | 2023 | Neuroprotection2023，1，1： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员